Galapagos

About

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel.

Mechelen-bovelingen,Limburg,Belgium
251 - 500
http://www.glpg.com

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: €5.20M
Industries: Biopharma,Biotechnology,Clinical Trials,Health Care,Medical
Founded date: Jan 1, 1999
Number Of Employee: 251 - 500
Operating Status: Active
Stock Symbol: vie:GLPG
Legal Name: Galapagos NV

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

15

€43.03M $5.40B

Galapagos has raised a total of €43.03M $5.40B in funding over 2 rounds. Their latest funding was raised on Jul 14, 2019 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 14, 2019	Post-IPO Equity	$5.10B	1	Gilead Sciences	—	Detail
Sep 17, 2018	Post-IPO Equity	$300M	—	—	—	Detail
Oct 5, 2017	IPO	—	—	—	—	Detail
Jan 22, 2015	Grant	€2.50M	1	—	—	Detail
Jan 13, 2014	Grant	€2.90M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

10

0

Galapagos has made 10 investments. Their most recent investment was on Aug 21, 2022, when DAM raised $1.80M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Aug 21, 2022 DAM	Pre-seed	$1.80M	Cryptocurrency	—
Jun 1, 2022 Altitude	Seed	$2.10M	Blockchain	—
Feb 23, 2022 Bware Labs	Series A	$6M	Blockchain	—
Dec 2, 2021 Ignite Tournaments	Seed	$3M	Blockchain	—
Dec 2, 2021 Ambire	Seed	$3.20M	Advertising	—

Investors

Number of Lead Investors

Number of Investors

6

Galapagos is funded by 6 investors. Gilead Sciences and Van Herk Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
Gilead Sciences	Yes	Post-IPO Equity
Van Herk Ventures	Yes	Post-IPO Equity
The Institute for the Promotion of Innovation by Science and Technology in Flanders	Yes	Grant
Thuja Capital	Yes	Series Unknown
University of Antwerp	—	Grant
Gilde Healthcare	—	Series Unknown

Employee Profiles

Number of Employee Profiles

16

Galapagos has 16 current employee profiles, including Executive Paul Stoffels

Executive

Executive

Executive

Board member

Executive

Acquisition

Galapagos has acquired 7 organizations. Their most recent acquisition was BioFocus DPI on Sep 21, 2005. They acquired BioFocus DPI for $36.50M.

Date Company Name	Industry	Acquisition Type	Price
Sep 21, 2005 BioFocus DPI	Life Science	acquisition	$ 36.50M	Detail
Dec 7, 2006 Inpharmatica	Biotechnology	acquisition	€ 19.10M	Detail
Jan 2, 2007 ProStrakan	Biopharma	acquisition	€ 31M	Detail
Feb 2, 2010 Argenta Discovery	Health Care	acquisition	—	Detail
Jan 15, 2013 Cangenix	Biotechnology	acquisition	—	Detail